Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11806365 | 0.89 | MAPT (0.53) | CYP1A2CYP2C9CYP2C19MAPTBCHE | |
| SCHEMBL8397383 | 0.89 | CYP1A2 (0.61) | CYP1A2CYP2C9CYP2C19MAPTBCHE | |
| SCHEMBL1697570 | 0.79 | ALDH1A1 (0.61) | CYP1A2CYP2C9CYP2C19MAPTALDH1A1 | |
| SCHEMBL28330814 | 0.79 | ALDH1A1 (0.61) | CYP1A2CYP2C9CYP2C19MAPTBCHE | |
| SCHEMBL2891507 | 0.78 | CYP1A2 (0.60) | CYP1A2CYP2C9CYP2C19ALDH1A1KDM4E | |
| SCHEMBL22660915 | 0.77 | ALDH1A1 (0.46) | CYP1A2CYP2C9CYP2C19MAPTBCHE | |
| Diethylamine SCHEMBL2890896 | 0.76 | MAPT (0.59) | CYP1A2CYP2C9MAPTALDH1A1KMT2A | |
| SCHEMBL28192447 | 0.76 | MAPT (0.43) | CYP1A2CYP2C9CYP2C19MAPTBCHE | |
| SCHEMBL22660943 | 0.75 | CYP1A2 (0.46) | CYP1A2CYP2C9CYP2C19MAPTBCHE | |
| SCHEMBL22660912 | 0.75 | CYP1A2 (0.46) | CYP1A2CYP2C9CYP2C19MAPTBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286197-A1 | Carboxamide Derivatives As Therapeutic Agents | TRANSTECH PHARMA, INC. | 2010-11-11 | — | — | US | disclosed |
| US-7776919-B2 | Carboxamide derivatives as therapeutic agents | TransTech Pharm, Inc. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7423177-B2 | Carboxamide derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080119512-A1 | Carboxamide Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| EP-1377295-A4 | CARBOXAMIDE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1377295-A2 | CARBOXAMIDE DERIVATIVES AS THERAPEUTIC AGENTS | Transtech Pharma, Inc. (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20020193432-A1 | Carboxamide derivatives as therapeutic agents | VTVX HOLDINGS I LLC | 2002-12-19 | — | — | US | disclosed |
| WO-2002070473-A2 | CARBOXAMIDE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286197-A1 | Carboxamide Derivatives As Therapeutic Agents | AGER, S100B, S100A4 | CYP1A2 3342/4885CYP2C9 3645/4885CYP2C19 3277/4885 |
| US-20020193432-A1 | Carboxamide derivatives as therapeutic agents | AGER, S100B, S100A4 | CYP1A2 3532/4885CYP2C9 3638/4885CYP2C19 3318/4885 |
| US-20080119512-A1 | Carboxamide Derivatives as Therapeutic Agents | AGER, S100B, S100A4 | CYP1A2 3342/4885CYP2C9 3645/4885CYP2C19 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.